Inspire Medical Systems, Inc. May 2025 NYSE: INSP Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ''may,'' ''will,'' ''should,'' ''expect,'' ''plan,'' ''anticipate,'' ''could,'' "future," "outlook," ''intend,'' ''target,'' ''project,'' ''contemplate,'' ' ...

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025. Monday, May 12th @ 4:30 p.m. ET Domestic:1-800-717 ...

ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Lyanne Harrison - Bank of America Margaret Kaczor - William Blair Davin Thillainathan - Goldman Sachs Anthony Petrone - Mizuho Group David Low - JPMorgan Saul Hadassin - Barrenjoey Dan Hurren - MST Matt Taylor - Jefferies Steve Wheen - J ...

By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating ...

Purple Innovation (PRPL) Q4 2024 Earnings Call March 14, 2025 01:36 AM ET Company Participants Stacy Turnof - Senior Vice PresidentRobert DeMartini - CEO & DirectorTodd Vogensen - Chief Financial OfficerBobby Griffin - Managing Director Conference Call Participants Matthew Koranda - MD & Senior Research AnalystBrian Nagel - MD & Senior Analyst - Consumer Growth & eCommerceJeremy Hamblin - Senior Research Analyst Operator Thank you for joining Purple Innovation's Fourth Quarter twenty twenty four Earnings Ca ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2024 Earnings Conference Call February 25, 2025 8:30 AM ET Company Participants Jeffrey Dayno - President, Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer, Scientific Officer Sandip Kapadia - Chief Financial Officer, Chief Administrative Officer Brennan Doyle - Head of Investor Relations Conference Call Participants Charles Duncan - Cantor Fitzgerald John Gregory Dean - Oppenheimer David Amsellem - Pipe ...